Viewing Study NCT00215878



Ignite Creation Date: 2024-05-05 @ 12:02 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00215878
Status: COMPLETED
Last Update Posted: 2012-07-09
First Post: 2005-09-18

Brief Title: D-serine for Posttraumatic Stress Disorder Treatment
Sponsor: Herzog Hospital
Organization: Herzog Hospital

Study Overview

Official Title: D-serine for Posttraumatic Stress Disorder Treatment
Status: COMPLETED
Status Verified Date: 2012-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder PTSD Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance depressive symptomatology that may be mediated by NMDA receptor function deficits

Thus enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine 2g dyand placebo This design allows each participant the opportunity to respond to the experimental treatment
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
20030311 None None None